TY - JOUR
T1 - Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort
AU - Little, Jayne
AU - Parker, Ben
AU - Lunt, Mark
AU - Hanly, John G.
AU - Urowitz, Murray B.
AU - Clarke, Ann E.
AU - Romero-Diaz, Juanita
AU - Gordon, Caroline
AU - Bae, Sang Cheol
AU - Bernatsky, Sasha
AU - Wallace, Daniel J.
AU - Merrill, Joan T.
AU - Buyon, Jill
AU - Isenberg, David A.
AU - Rahman, Anisur
AU - Ginzler, Ellen M.
AU - Petri, Michelle
AU - Dooley, Mary Anne
AU - Fortin, Paul
AU - Gladman, Dafna D.
AU - Steinsson, Kristjan
AU - Ramsey-Goldman, Rosalind
AU - Khamashta, Munther A.
AU - Aranow, Cynthia
AU - Mackay, Meggan
AU - Alarcón, Graciela S.
AU - Manzi, Susan
AU - Nived, Ola
AU - Jönsen, Andreas
AU - Zoma, Asad A.
AU - van Vollenhoven, Ronald F.
AU - Ramos-Casals, Manuel
AU - Ruiz-Irastorza, Guillermo
AU - Lim, Sung Sam
AU - Kalunian, Kenneth C.
AU - Inanc, Murat
AU - Kamen, Diane L.
AU - Peschken, Christine A.
AU - Jacobsen, Soren
AU - Askanase, Anca
AU - Sanchez-Guerrero, Jorge
AU - Bruce, Ian N.
N1 - Funding Information:
This study was funded by an unrestricted grant from UCB Pharma.A.E.C. holds The Arthritis Society Research Chair in Rheumatic Diseases at the University of Calgary. J.G.H.'s work was supported by the Canadian Institutes of Health Research (research grant MOP-88526). C.G.'s work was supported by Lupus UK, Sandwell and West Birmingham Hospitals NHS Trust and the National Institute for Health Research (NIHR)/Wellcome Trust Clinical Research Facility in Birmingham. S.-C.B.'s work was supported by unrestricted grant (Hanyang University 201600000001387). The Montreal General Hospital Lupus Clinic is partially supported by the Singer Family Fund for Lupus Research. A.R.'s work was funded by LUPUS UK, The Rosetrees Trust and Arthritis Research UK Programme Grant 19423 and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. D.A.I. is supported by Arthritis Research UK Grant 20164. The Hopkins Lupus Cohort is supported by the National Institute of Health (NIH) (grant AR43727). P.F. presently holds a tier 1 Canada Research Chair on Systemic Autoimmune Rheumatic Diseases at Université Laval, and part of this work was done while he was still holding a Distinguished Senior Investigator of The Arthritis Society. I.N.B. is an NIHR Senior Investigator and is funded by Arthritis Research UK, the National Institute for Health Research Manchester Biomedical Research Unit and the NIHR/Wellcome Trust Manchester Clinical Research Facility. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. B.P. is supported by National Institute for Health Research Manchester Biomedical Research Unit and the NIHR/Welcome Trust Manchester Clinical Research Facility. S.J. is supported by the Danish Rheumatism Association (A1028) and the Novo Nordisk Foundation (A05990). R.R.-G.'s work was supported by the NIH (grants 8UL1TR000150 formerly UL-1RR-025741, K24-AR-02318 and P60AR064464 formerly P60-AR-48098). M.A.D.'s work was supported by the NIH grant RR00046. G.R.-I. is supported by the Department of Education, Universities and Research of the Basque Government.
Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Objectives. To describe glucocorticoid (GC) use in the SLICC inception cohort and to explore factors associated with GC use. In particular we aimed to assess temporal trends in GC use and to what extent physician-related factors may influence use. Methods. Patients were recruited within 15 months of diagnosis of SLE from 33 centres between 1999 and 2011 and continue to be reviewed annually. Descriptive statistics were used to detail oral and parenteral GC use. Cross sectional and longitudinal analyses were performed to explore factors associated with GC use at enrolment and over time. Results. We studied 1700 patients with a mean (S.D.) follow-up duration of 7.26 (3.82) years. Over the entire study period, 1365 (81.3%) patients received oral GCs and 447 (26.3%) received parenteral GCs at some point. GC use was strongly associated with treatment centre, age, race/ethnicity, sex, disease duration and disease activity. There was no change in the proportion of patients on GCs or the average doses of GC used over time according to year of diagnosis. Conclusion. GCs remain a cornerstone in SLE management and there have been no significant changes in their use over the past 10-15 years. While patient and disease factors contribute to the variation in GC use, between-centre differences suggest that physician-related factors also contribute. Evidence-based treatment algorithms are needed to inform a more standardized approach to GC use in SLE.
AB - Objectives. To describe glucocorticoid (GC) use in the SLICC inception cohort and to explore factors associated with GC use. In particular we aimed to assess temporal trends in GC use and to what extent physician-related factors may influence use. Methods. Patients were recruited within 15 months of diagnosis of SLE from 33 centres between 1999 and 2011 and continue to be reviewed annually. Descriptive statistics were used to detail oral and parenteral GC use. Cross sectional and longitudinal analyses were performed to explore factors associated with GC use at enrolment and over time. Results. We studied 1700 patients with a mean (S.D.) follow-up duration of 7.26 (3.82) years. Over the entire study period, 1365 (81.3%) patients received oral GCs and 447 (26.3%) received parenteral GCs at some point. GC use was strongly associated with treatment centre, age, race/ethnicity, sex, disease duration and disease activity. There was no change in the proportion of patients on GCs or the average doses of GC used over time according to year of diagnosis. Conclusion. GCs remain a cornerstone in SLE management and there have been no significant changes in their use over the past 10-15 years. While patient and disease factors contribute to the variation in GC use, between-centre differences suggest that physician-related factors also contribute. Evidence-based treatment algorithms are needed to inform a more standardized approach to GC use in SLE.
KW - Epidemiology
KW - Glucocorticoids
KW - Systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=85045074075&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045074075&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/kex444
DO - 10.1093/rheumatology/kex444
M3 - Article
C2 - 29361147
AN - SCOPUS:85045074075
SN - 1462-0324
VL - 57
SP - 677
EP - 687
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 4
ER -